Clinical Application of Umbilical Cord Mesenchymal Stem Cells Preserves β-cells in Type 1 Diabetes.

IF 5.4 2区医学 Q1 CELL & TISSUE ENGINEERING

Stem Cells Translational Medicine Pub Date : 2024-02-14 DOI:10.1093/stcltm/szad077

Ashraf Al Madhoun, Lubaina Koti, Neus Carrió, Maher Atari, Fahd Al-Mulla

{"title":"Clinical Application of Umbilical Cord Mesenchymal Stem Cells Preserves β-cells in Type 1 Diabetes.","authors":"Ashraf Al Madhoun, Lubaina Koti, Neus Carrió, Maher Atari, Fahd Al-Mulla","doi":"10.1093/stcltm/szad077","DOIUrl":null,"url":null,"abstract":"<p><p>Type 1 diabetes (T1D) is a chronic autoimmune disease associated with complications that reduce the quality of life of affected individuals and their families. The therapeutic options for T1D are limited to insulin therapy and islet transplantation; these options are not focused on preserving β-cell function and endogenous insulin. Despite the promising outcomes observed in current clinical trials involving allogeneic Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) infusion for the management of T1D, the precise underlying mechanism of action remains to be elucidated. In this correspondence, we propose prospective mechanisms of action of WJ-MSCs that may be mediating their observed capability to preserve β-cell function and prevent T1D progression and provide recommendations for further investigations in clinical settings. We also highlight the efficacy of WJ-MSCs for therapeutic applications in comparison to other adult MSCs. Finally, we recommend the participation of muti-centers governed by international organizations to implement guidelines for the safe practice of cell therapy and patients' welfare.</p>","PeriodicalId":21986,"journal":{"name":"Stem Cells Translational Medicine","volume":" ","pages":"101-106"},"PeriodicalIF":5.4000,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10872683/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem Cells Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/stcltm/szad077","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}

引用次数: 0

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease associated with complications that reduce the quality of life of affected individuals and their families. The therapeutic options for T1D are limited to insulin therapy and islet transplantation; these options are not focused on preserving β-cell function and endogenous insulin. Despite the promising outcomes observed in current clinical trials involving allogeneic Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) infusion for the management of T1D, the precise underlying mechanism of action remains to be elucidated. In this correspondence, we propose prospective mechanisms of action of WJ-MSCs that may be mediating their observed capability to preserve β-cell function and prevent T1D progression and provide recommendations for further investigations in clinical settings. We also highlight the efficacy of WJ-MSCs for therapeutic applications in comparison to other adult MSCs. Finally, we recommend the participation of muti-centers governed by international organizations to implement guidelines for the safe practice of cell therapy and patients' welfare.

查看原文本刊更多论文

脐带间充质干细胞保存β-细胞在1型糖尿病中的临床应用

1型糖尿病(T1D)是一种慢性自身免疫性疾病，其并发症会降低患者及其家人的生活质量。T1D的治疗选择仅限于胰岛素治疗和胰岛移植;这些选择的重点不是保持β细胞功能和内源性胰岛素。尽管在目前的临床试验中，同种异体Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs)输注治疗T1D取得了令人鼓舞的结果，但其确切的潜在作用机制仍有待阐明。在这篇通信中，我们提出了WJ-MSCs的潜在作用机制，这些机制可能介导了它们所观察到的保护β细胞功能和预防T1D进展的能力，并为进一步的临床研究提供了建议。与其他成人间充质干细胞相比，我们还强调了WJ-MSCs在治疗应用方面的功效。最后，我们建议由国际组织管理的多中心参与，以实施细胞治疗的安全实践和患者的福利准则。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Stem Cells Translational Medicine CELL & TISSUE ENGINEERING-

CiteScore

12.90

自引率

3.30%

发文量

140

审稿时长

6-12 weeks

期刊介绍： STEM CELLS Translational Medicine is a monthly, peer-reviewed, largely online, open access journal. STEM CELLS Translational Medicine works to advance the utilization of cells for clinical therapy. By bridging stem cell molecular and biological research and helping speed translations of emerging lab discoveries into clinical trials, STEM CELLS Translational Medicine will help move applications of these critical investigations closer to accepted best patient practices and ultimately improve outcomes. The journal encourages original research articles and concise reviews describing laboratory investigations of stem cells, including their characterization and manipulation, and the translation of their clinical aspects of from the bench to patient care. STEM CELLS Translational Medicine covers all aspects of translational cell studies, including bench research, first-in-human case studies, and relevant clinical trials.